GLP-1 receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-02. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
In order to prevent oxidation of the secondary alcohols with potassium permanganate, they are protected via acetalation with acetone and then deprotected after the oxidation of the primary alcohols to carboxylic acids. A very spectacular example application of protecting groups from natural product synthesis is the 1994 total synthesis of palytoxin acid by Yoshito Kishi's research group. Here 42 functional groups (39 hydroxyls, one diol, an amine group, and a carboxylic acid) required protection. These proceeded through 8 different protecting groups (a methyl ester, five acetals, 20 TBDMS esters, nine p‑methoxybenzyl ethers, four benzoates, a methyl hemiacetal, an acetone acetal and an SEM ester).
=== Optical sensors === Polymer optical fibers have generated increasing interest in recent years. Because of low cost, ease of handling, long wavelength transparency, great flexibility, and biocompatibility, polymer optical fibers show great potential for short-distance networking, optical sensing and power delivery. Electrospun nanofibers are particularly well-suitable for optical sensors because sensor sensitivity increases with increasing surface area per unit mass. Optical sensing works by detecting ions and molecules of interest via fluorescence quenching mechanism. Wang et al. successfully developed nanofibrous thin film optical sensors for metal ion (Fe3+ and Hg2+) and 2,4-dinitrotoluene (DNT) detection using the electrospinning technique. Quantum dots show useful optical and electrical properties, including high optical gain and photochemical stability. A variety of quantum dots have been successfully incorporated into polymer nanofibers. Meng et al. showed that quantum dot-doped polymer nanofiber sensor for humidity detection shows fast response, high sensitivity, and long-term stability while requiring low power consumption. Kelly et al. developed a sensor that warns first responders when the carbon filters in their respirators have become saturated with toxic fume particles. The respirators typically contain activated charcoal that traps airborne toxins. As the filters become saturated, chemicals begin to pass through and render the respirators useless.
=== Retinoic acids and photodamage === UV radiation decreases the expression of both retinoic acid receptors and retinoid x receptors in human skin, thereby resulting in a complete loss of the induction of RA-responsive genes. It also leads to an increase in activity of the AP-1 pathway, increasing MMP activity and thus resulting in a functional deficiency of vitamin A in the skin.
=== Blood–brain barrier === Efflux by P-glycoprotein also prevents circulating loperamide from effectively crossing the blood-brain barrier, so it can generally only agonize mu-opioid receptors in the peripheral nervous system, and currently has a score of one on the anticholinergic cognitive burden scale. Concurrent administration of P-glycoprotein inhibitors such as quinidine potentially allows loperamide to cross the blood-brain barrier and produce central morphine-like effects. At high doses (>70mg), loperamide can saturate P-glycoprotein (thus overcoming the efflux) and produce euphoric effects. Loperamide taken with quinidine was found to produce respiratory depression, indicative of central opioid action. High doses of loperamide have been shown to cause a mild physical dependence during preclinical studies, specifically in mice, rats, and rhesus monkeys. Symptoms of mild opiate withdrawal were observed following abrupt discontinuation of long-term treatment of animals with loperamide.
== Medical uses == Olipudase alfa is indicated as an enzyme replacement therapy for the treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency in people with type A/B or type B. Olipudase alfa is an enzyme replacement therapy, developed to replace patients' deficient or defective enzyme, acid sphingomyelinase, and thereby reduce fat accumulation within cells and relieve some of the symptoms of the disease. Xenpozyme was approved by the European Medicines Agency for the treatment of acid sphingomyelinase deficiency type A/B or type B, and by the US FDA for the treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency.
Sources: en.wikipedia.org
Serotonin taken orally does not pass into the serotonergic pathways of the central nervous system, because it does not cross the blood–brain barrier. However, tryptophan and its metabolite 5-hydroxytryptophan (5-HTP), from which serotonin is synthesized, do cross the blood–brain barrier. These agents are available as dietary supplements and in various foods, and may be effective serotonergic agents. One product of serotonin breakdown is 5-hydroxyindoleacetic acid (5-HIAA), which is excreted in the urine. Serotonin and 5-HIAA are sometimes produced in excess amounts by certain tumors or cancers, and levels of these substances may be measured in the urine to test for these tumors.
M. Marcu-Pipeline conveyors(pneumatic wheeled pipeline conveyors-state of the art/photos-1990) at page 45 in the "Material handling in pyrometallurgy": proceedings of the International Symposium on Materials Handling in Pyrometallurgy, Hamilton, Ontario, August 26–30, 1990 Twigge-Molecey, T. Price, Metallurgical Society of CIM. Non-Ferrous Pyrometallurgy Section Pergamon Press, Sep 30, 1990 - Technology & Engineering - 227 pages
=== Use by non-military groups === Terrorist groups have used C-4 worldwide in acts of terrorism and insurgency, as well as domestic terrorism and state terrorism. On May 13, 1985, the Philadelphia Police Department dropped a C-4 bomb on the home of the MOVE organization, killing eleven people — including five children — and wiping out 61 homes in two city blocks in a subsequent fire. Composition C-4 is recommended in al-Qaeda's traditional curriculum of explosives training. In October 2000, the group used C-4 to attack the USS Cole, killing 17 sailors. In 1996, Saudi Hezbollah terrorists used C-4 to blow up the Khobar Towers, a U.S. military housing complex in Saudi Arabia. Composition C-4 has also been used in improvised explosive devices by Iraqi insurgents.
== Nomenclature == This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH2 group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is L-alanine:NAD+ oxidoreductase (deaminating). Other names in common use include AlaDH, L-alanine dehydrogenase, NAD+-linked alanine dehydrogenase, alpha-alanine dehydrogenase, NAD+-dependent alanine dehydrogenase, alanine oxidoreductase, and NADH-dependent alanine dehydrogenase. T
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。